This test was developed and its performance characteristics determined by Marshfield Labs. It has not been cleared or approved by the US Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research.
This assay is a semi-quantitative confirmatory test by liquid chromatography/tandem mass spectrometry (LC/MSMS). If an analyte or its corresponding metabolites are present in urine, it indicates that the patient has used the respective drugs recently. If a drug is detected, it will be reported as “present”, in three concentration ranges (low, moderate, and high) with the analyte’s specific ranges. The test includes seven amines: amphetamine, methamphetamine, MDA, MDMA, MDEA, methylphenidate, ritalinic acid; six benzodiazepines: 7-aminoclonazepam, lorazepam, oxazepam, alphahydroxyalprazolam, nordiazepam, temazepam; seventeen opiates: buprenorphine, norbuprenorphine (buprenorphine metabolite), oxycodone, nor-oxycodone (oxycodone metabolite), oxymorphone (oxycodone metabolite), morphine, hydromorphone, 6-monoacetylmorphine (heroin metabolite), codeine, hydrocodone, gabapentin, tramadol, nor-tramadol (tramadol metabolite), fentanyl, nor-fentanyl (fentanyl metabolite), EDDP (methadone metabolite), and methadone. Analytes below the level of detection level will be reported as “not detected”.
This test is developed in-house with targeted analytes in consultation with pain management providers. The objective of this test is to provide useful information to help determine patient compliance or identify misuse of other drugs commonly present in our patient population.
Please see this document for a full list of drugs included in this panel, along with the detection levels of each: TDPU Test Components
NOTE: If other drug classes are also of interest (cannabinoids, cocaine, barbiturates, ethanol), it is recommended that the PCS4WO test be ordered along with this test.